Genmab — April 2018

[Solsen]

Det kunne give usikkerhed til virkning. Bivirkninger er sikkert små og ubetydelige.

[Bulder]

I Mirror prøvede man 3, 30 og 60 mg. På CT står dosis størrelsen faktisk ikke for fase 3. Men her skriver de at 30 mg eller mere var bedst. https://mymsaa.org/publications/msresearch-update-2017/ofatumumab/

[Solsen]

Jeg mener dosis ligger under 30 mg.

[bibob]

God morgen fra Solkysten.

[polle1]

God morgen fra Nordkysten

[Helge_LarsenPI-redaktør]

God morgen fra baglokalet i familiens butik i Rødovre Centrum.

[rex_pacis]

God formiddag fra Amager

[Bulder]

Så er spørgsmålet om det vil give ekstra at tilføje dara http://onkologisktidsskrift.dk/behandlinger/lungekraeft/758-nsclc-patienter-overlever-med-lungekraeft-efter-tecentriq-behandling.html

[Bulder]

Keytruda klarer sig også fint i nsclc. http://onkologisktidsskrift.dk/behandlinger/lungekraeft/763-peter-meldgaard-keytruda-kombination-oger-overlevelsen-markant-for-nsclc.html

[Bulder]

Der kører ikke kombiforsøg med dara-pembro i nsclc. Kun i RRMM og et blandet i NHL.

[E_L]

Onclive article : Novel Approaches Emerge in AL Amyloidosis
https://www.onclive.com/web-exclusives/novel-approaches-emerge-in-al-amyloidosis

[E_L]

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - https://clinicaltrials.gov/ct2/show/study/NCT00574288?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=1&sect=X01256 - results posted

[E_L]

we have seen these before; it is GEN501

[E_L]

most of these hospitals finished
recruiting now on this (D-RVd) trial, some even complete https://clinicaltrials.gov/ct2/show/study/NCT02874742?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=2&show_locs=Y#locn

[E_L]

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP) was Terminated https://clinicaltrials.gov/ct2/show/NCT01612988?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=4
(which makes sense, it wasnt even a Novartis study)

[E_L]

Onclive video : Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

• https://www.onclive.com/onclive-tv/dr-voorhees-on-treatments-for-patients-with-relapsed-multiple-myeloma

[Bulder]

Very uplifting E L. They have also changed the primary completion date for the Griffin study from nov. 4. 2019 to dec. 31. 2018! A whole year. I wouldn't be surprised if they chose to file on that study. Even though it's only a phase 2. That would mean filing on the last frontline segment already next year.

[Bulder]

We already have Alcyone. Maia and Cassiopeia will com soon. The only left is Griffin. Then the whole fronline settting is covered.

[Bulder]

Maybe it is a little early to expect a filing on the basis of Griffin. In November Winkel said: "Janssen is currently planning a Phase 3 study in D-RVd, and the Phase 2 data if
positive could be included in a compendium listing."

[GeorgeBest]

E L & Bulder. So are so diligent, even in the weekends. Thanks a lot. We all profit from it....